Shionogi set to take OncoTherapy head and neck cancer vaccine into clinic
This article was originally published in Scrip
Executive Summary
OncoTherapy Science (OTS) will receive an undisclosed milestone payment from Shionogi following a filing by its partner to begin clinical trials with a peptide "cocktail" cancer vaccine.